112 related articles for article (PubMed ID: 12719749)
1. Continuing education: The emergence of thalidomide in treating advanced renal cell carcinoma.
Wood LS; Perez C; Monroe D
Oncol Nurs Forum; 2003; 30(3):501-11. PubMed ID: 12719749
[TBL] [Abstract][Full Text] [Related]
2. Concepts in advanced renal carcinoma.
Esper P
Semin Oncol Nurs; 2012 Aug; 28(3):170-9. PubMed ID: 22846485
[TBL] [Abstract][Full Text] [Related]
3. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Harshman LC; Li M; Srinivas S
Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
[TBL] [Abstract][Full Text] [Related]
4. Node positive renal cell cancer. Who can be helped?
Messing EM
Eur Urol; 2007 Jun; 51(6):1477-8. PubMed ID: 17240037
[No Abstract] [Full Text] [Related]
5. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
[TBL] [Abstract][Full Text] [Related]
6. Renal cell carcinoma: a reappraisal.
Patel C; Ahmed A; Ellsworth P
Urol Nurs; 2012; 32(4):182-90; quiz 191. PubMed ID: 22977986
[TBL] [Abstract][Full Text] [Related]
7. Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.
Harshman LC; Srinivas S
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1749-61. PubMed ID: 18062749
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.
Margulis V; Matin SF; Tannir N; Tamboli P; Shen Y; Lozano M; Swanson DA; Jonasch E; Wood CG
Urology; 2009 Feb; 73(2):337-41. PubMed ID: 18950837
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide for recurrent renal-cell cancer in a 40-year-old man.
Amato R
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):33-6. PubMed ID: 11204672
[TBL] [Abstract][Full Text] [Related]
10. Rebuttal from authors re: Edward M. Messing. Node positive renal cell cancer. Who can be helped? Eur Urol 2007;51:1477-8.
Karakiewicz P; Perrotte P; Trinh QD; Patard JJ
Eur Urol; 2007 Jun; 51(6):1478-80. PubMed ID: 17275988
[No Abstract] [Full Text] [Related]
11. [The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma].
Leroy X; Edeline J; Rioux-Leclercq N
Ann Pathol; 2011 Dec; 31(6):466-71. PubMed ID: 22172119
[TBL] [Abstract][Full Text] [Related]
12. International consultation on urologic diseases and the European Association of Urology international consultation on locally advanced renal cell carcinoma.
Margulis V; Master VA; Cost NG; Leibovich BC; Joniau S; Kuczyk M; Mulders PF; Kirkali Z; Wirth MP; Hirao Y; Rawal S; Chong TW; Wood CG
Eur Urol; 2011 Oct; 60(4):673-83. PubMed ID: 21752533
[TBL] [Abstract][Full Text] [Related]
13. [Radiotherapy in treatment of relapsing renal cell cancer].
Metelev VV; Zharinov GM
Vopr Onkol; 2008; 54(6):775-7. PubMed ID: 19241859
[No Abstract] [Full Text] [Related]
14. Diagnosis and treatment of renal cell carcinoma in children: a report from the Polish pediatric rare tumor study group.
Stachowicz-Stencel T; Bien E; Balcerska A; Godzinski J; Synakiewicz A; Perek-Polnik M; Kurylak A; Pietras W; Kuzmicz M; Mizia-Malarz A; Rybczynska A; Nurzynska-Flak J
Klin Padiatr; 2011 May; 223(3):138-41. PubMed ID: 21509711
[TBL] [Abstract][Full Text] [Related]
15. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG
Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919
[TBL] [Abstract][Full Text] [Related]
16. Kidney cancer. Clinical practice guidelines.
Motzer RJ; Carducci MA; Fishman M; Hancock SL; Hauke RJ; Hudes GR; Kantoff P; Kuzel TM; Lange PH; Levine EG; Logothetis C; Margolin KA; Pili R; Pohar KS; Redman BG; Richey S; Robertson CN; Samlowski WE; Sheinfeld J; Urban DA;
J Natl Compr Canc Netw; 2005 Jan; 3(1):84-93. PubMed ID: 19813325
[No Abstract] [Full Text] [Related]
17. High-dose interleukin-2 in metastatic renal cell carcinoma.
Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
[No Abstract] [Full Text] [Related]
18. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.
Pacheco AV; Rasila K; Lee SJ; Rabinowitz I; Elias L; Lee FC; Verschraegen CF
Urol Oncol; 2008; 26(6):610-5. PubMed ID: 18367103
[TBL] [Abstract][Full Text] [Related]
19. Major response and clinical benefit following third-line treatment for Bellini duct carcinoma.
Fakhrai N; Haitel A; Balassy C; Zielinski CC; Schmidinger M
Wien Klin Wochenschr; 2005 Jan; 117(1-2):63-5. PubMed ID: 15986594
[TBL] [Abstract][Full Text] [Related]
20. Improving outcomes in patients with advanced renal cell carcinoma.
Sosman JA
Expert Rev Anticancer Ther; 2008 Mar; 8(3):481-90. PubMed ID: 18366295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
